(Q42990190)

12 November 2017

title

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

2

1 reference

12 November 2017

D T Lau

1

1 reference

12 November 2017

M G Ghany

3

1 reference

12 November 2017

Y Park

4

1 reference

12 November 2017

P Schmid

5

1 reference

12 November 2017

J H Hoofnagle

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

12 November 2017

1 reference

12 November 2017

volume

28

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

1121-1127

1 reference

Transfusion-Associated Hepatitis Not Due to Viral Hepatitis Type A or B

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Detection of hepatitis C viral sequences in non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Hepatitis C and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Therapy of hepatitis C: interferon alfa-2a trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Therapy of hepatitis C: interferon alfa-n1 trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280430

7 January 2021

Identifiers

DOI

10.1002/HEP.510280430

1 reference

12 November 2017

1 reference